[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563969":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":52,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"CerbaXpert","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Infected patients",null,"Patients infected with hepatitis B virus",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Sabrina KALI, Dr.","CONTACT","33762376831","kali.rinasab@gmail.com",[19,37],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Cerba Xpert","NOT_YET_RECRUITING","Frépillon","Ile de Franace","95000","France","FR",{"type":28,"coordinates":29},"Point",[30,31],2.20528,49.05216,{"lat":31,"lon":30},[34],{"name":14,"role":15,"phone":35,"phoneExt":10,"email":36},"00337632376831","skali@cerbaresearch.com",{"facility":38,"status":39,"city":25,"state":40,"zip":41,"country":25,"countryCode":26,"cosmosGeoPoint":42,"geoPoint":46,"contacts":47},"Cerballiance Chemin vert","RECRUITING","Paris","75000",{"type":28,"coordinates":43},[44,45],-0.84802,45.60366,{"lat":45,"lon":44},[48],{"name":49,"role":15,"phone":50,"phoneExt":10,"email":51},"Sabrina Kali Dr. Sabrina Kali, Doctor","+33 621441566","sabrina.kali@cerbaxpert.com",{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[55],{"name":56,"class":57},"Bioneer Corporation","UNKNOWN","100563969","accupower--hbv-performance-evaluation-quant-kit-bioneer-existation-fa-96384-100563969",false,"NCT06623071","Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96\u002F384","Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation™FA 96\u002F384","BIOPERF-HBV","Inclusion Criteria:\n\nThe patient to be included in this study must be able to understand the purpose research, in order to give free and informed consent.\n\n* Subject aged over 18\n* Subject presenting himself at the investigation center and responding to one of these two criteria:\n\n  * Subject presenting with a prescription for determination HBV viral load\n  * Subject with previously confirmed HBV infection by CE marked tests.\n* Subject capable of understanding the aim of the research having given express free and informed consent\n* Subject affiliated to or beneficiary of a social security system\n\nExclusion Criteria:\n\nProtected subject: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial decision or administrative\n\n• Subject participating in another clinical study","ALL","18 Years",{"count":69,"type":70},45,"ESTIMATED","1 Day","OBSERVATIONAL","As part of the CE marking of a hepatitis B diagnostic kit, the South Korean manufacturer Bioneer wishes to set up a performance study in France in accordance with the IVDR (RE 2017\u002F746).\n\nCerba Xpert CRO of the Cerba Healthcare group promoted this performance study by setting up a prospective collection of blood samples from patients with hepatitis B virus and whose viral load is positive. This prospective collection will be carried out in 3 laboratories of the Cerba Healthcare group.",[75],"Hepatitis B",[77],"HBV","2025-03-24",{"date":80,"type":81},"2025-03-26","ACTUAL",{"date":83,"type":81},"2024-10-01",{"date":85,"type":70},"2025-05-31",{"name":5,"class":6},2]